Filtered By:
Cancer: Prostate Cancer

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 879 results found since Jan 2013.

Auranofin, an Anti-rheumatic Gold Drug, Aggravates the Radiation-Induced Acute Intestinal Injury in Mice
Conclusion In this study, we found that a non-toxic dose of auranofin significantly aggravated the severity of the radiation-induced intestinal injury. This suggests that auranofin treatment can be an independent factor that influences the risk of intestinal complications after pelvic or abdominal radiotherapy. Ethics Statement All the protocols used in this study were approved by the Institutional Animal Care and Use Committee of the Korean Institute of Radiological and Medical Sciences (IACUC permit number: KIRAMS217-0007). Author Contributions H-JL, JS, and Y-BL designed the experiments. EL and JK conducted the exp...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Ion exchange liquid chromatography method for the direct determination of small ribonucleic acids.
We present here a one step sample preparation combined with non-denaturing anion exchange chromatography with UV detection for the quantitation of siRNA and its chain shortened metabolites. The sample preparation uses a novel lysis buffer with proteinase K to effectively isolate siRNA from cells and formulated media with greater than 95% recovery. The ion exchange chromatography allows for a lower limit of quantitation of 6ngmL(-1) in cells and media equivalent to 6ng/200,000cells. This method is applied to study the uptake of siRNA in prostate cancer cells and the disappearance in the media and siRNA metabolism. siRNA met...
Source: Analytica Chimica Acta - October 7, 2013 Category: Chemistry Authors: McGinnis AC, Cummings BS, Bartlett MG Tags: Anal Chim Acta Source Type: research

Glycogen-nucleic acid constructs for gene silencing in multicellular tumor spheroids.
Abstract The poor penetration of nanocarrier-siRNA constructs into tumor tissue is a major hurdle for the in vivo efficacy of siRNA therapeutics, where the ability of the constructs to permeate the 3D multicellular matrix is determined by their physicochemical properties. Herein, we optimized the use of soft glycogen nanoparticles for the engineering of glycogen-siRNA constructs that can efficiently penetrate multicellular tumor spheroids and exert a significant gene silencing effect. Glycogen nanoparticles from different bio-sources and with different structural features were investigated. We show that larger gl...
Source: Biomaterials - May 20, 2018 Category: Materials Science Authors: Wojnilowicz M, Besford QA, Wu YL, Loh XJ, Braunger JA, Glab A, Cortez-Jugo C, Caruso F, Cavalieri F Tags: Biomaterials Source Type: research

Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation
CONCLUSIONS: In conclusion, down-regulation of FAP-α can inhibit the invasion and proliferation of prostate cancer. Our study provides a theoretical basis for the targeted treatment of prostate cancer.PMID:35129203 | DOI:10.14670/HH-18-430
Source: Histology and Histopathology - February 7, 2022 Category: Cytology Authors: Jiali An Dingkun Hou Lei Wang Lili Wang Yuanyuan Yang Haitao Wang Source Type: research

Small interference RNA-mediated silencing of prostate stem cell antigen attenuates growth, reduces migration and invasion of human prostate cancer PC-3M cells
Conclusions: The present study provides the first evidence that silencing PSCA using siRNA can inhibit the proliferation and invasiveness properties of human CaP cells, which may provide a promising therapeutic strategy for CaP and open a novel avenue toward the investigation of the role of PSCA overexpression in cancers.
Source: Urologic Oncology: Seminars and Original Investigations - March 24, 2011 Category: Urology & Nephrology Authors: Zhigang Zhao, Wenjing Ma, Guohua Zeng, Defeng Qi, Lili Ou, Yeping Liang Tags: Clinical - Prostate Source Type: research

PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth
Abstract: The down-regulation of Notch1 by small interfering RNA (siRNA) can significantly inhibit human prostate cancer cell growth. The delivery of siRNA into specific cells is a key requirement for its clinical application. Recent reports have indicated that antibody-mediated siRNA delivery is an effective approach for targeted knockdown of specific genes in appropriate cells. Prostate-specific membrane antigen (PSMA) is regarded as an ideal target for the delivery of therapeutic agents to prostate cancer cells. The purpose of the present study was to evaluate whether siRNA can be efficiently delivered into PSMA-positiv...
Source: Cancer Letters - July 1, 2013 Category: Cancer & Oncology Authors: Yansheng Su, Liang Yu, Na Liu, Zhangyan Guo, Guodong Wang, Jia Zheng, Ming Wei, He Wang, An-gang Yang, Weijun Qin, Weihong Wen Tags: Research Articles Source Type: research

Abstract 4590: Cisplatin-RNAi nanotherapeutics for synergistic anti-tumor activity
Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, the development of acquired chemoresistance is a persistent clinical problem limiting the successful treatment of malignancies and considerable work has been done to identify the molecular mechanisms involved. Many possible mechanisms have been suggested for platinum resistance emergence, such as drug efflux, apoptosis inhibition among others. Recent studies have shown that the suppression of crucial gene products (e.g. REV1, REV3L) involved in the error-prone translesion DNA synthesis pathway can sensitiz...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Xu, X., Zhang, X., Xie, K., Walker, G., Farokhzad, O. Tags: Experimental and Molecular Therapeutics Source Type: research

Nanotherapy Silencing the Interleukin-8 Gene Produces Regression of Prostate Cancer by Inhibition of Angiogenesis.
This study examines the role of IL-8 in the pathogenesis of metastatic prostate cancer. We developed a biocompatible, cationic polylactide (CPLA) nanocarrier to complex with and efficiently deliver IL-8 siRNA to CaP cells in vitro and in vivo. CPLA IL-8 siRNA nanocomplexes (nanoplexes) protect siRNA from rapid degradation, are nontoxic, have a prolonged lifetime in circulation, and their net positive charge facilitates penetration of cell membranes and subsequent intracellular trafficking. Administration of CPLA IL-8 siRNA nanoplexes to immunodeficient mice bearing human CaP tumors produced significant antitumor activities...
Source: Immunology - May 8, 2016 Category: Allergy & Immunology Authors: Aalinkeel R, Nair B, Chen CK, Mahajan SD, Reynolds JL, Zhang H, Sun H, Sykes DE, Chadha KC, Turowski SG, Bothwell KD, Seshadri M, Chen C, Schwartz SA Tags: Immunology Source Type: research

Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.
CONCLUSIONS: SCCRO is associated with progression and prognosis of PC. After SCCRO gene was transferred, the growth of Lncap cells was inhibited, and ability of invasion and migration decreased by reducing the expression of FAK and MMP-2. SCCRO has potential to become a new target for the treatment of PC. PMID: 29077169 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 28, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

lncRNA ZEB1-AS1 Mediates Oxidative Low-Density Lipoprotein-Mediated Endothelial Cells Injury by Post-transcriptional Stabilization of NOD2
Conclusion We report the discovery that ZEB1-AS1 functionally participates in ox-LDL-induced ECs injury via LRPPRC-mediated stabilization of NOD2. Uncovering the precise role of ZEB1-AS1/LRPPRC/NOD2 pathway in the progression of ox-LDL-induced ECs death and AS will not only increase our knowledge of ox-LDL-induced AS, but also enable the development of novel therapeutic strategies to overcome oxidation product-induced diseases. Author Contributions XX and CL designed and mainly did the study. CM, ZD, and YD helped and did the study. Conflict of Interest Statement The authors declare that the research was conducted in ...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer
Cancer Biol Ther. 2022 Dec 31;23(1):163-172. doi: 10.1080/15384047.2021.2024040.ABSTRACTExtracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules between cells. As natural vehicles, EVs may exhibit higher delivery efficiency, lower immunogenicity, and better compatibility than existing RNA carriers. A major limitation of their therapeutic use is the shortage of efficient, robust, and scalable methods to load siRNA of interest. Here, we report a novel strategy using polycationic membrane-penetrating peptide TAT to encapsulate siRNAs into EVs...
Source: Cancer Biology and Therapy - February 16, 2022 Category: Cancer & Oncology Authors: Yanjun Diao Gangqiang Wang Bingbing Zhu Zhuo Li Shan Wang Lijuan Yu Rui Li Weixiao Fan Yue Zhang Lei Zhou Liu Yang Xiaoke Hao Jiayun Liu Source Type: research

Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin.
Abstract The main goal of this work was to assess in vitro the potential of Polo-like kinase gene (PLK-1) as a molecular target within the tumor microenvironment, namely in both cancer cells of tumors of different histological origin and endothelial cells from angiogenic blood vessels, upon silencing with anti-PLK-1 siRNA. In addition, the effect of Plk-1 downregulation on the cancer cells chemosensitization to paclitaxel was further assessed. Downregulation of Plk-1 reduced cancer cells viability from 40 to 85% and up to 59% in endothelial cells. Regarding the latter, it compromised their ability to form new tube...
Source: Current Gene Therapy - March 25, 2013 Category: Genetics & Stem Cells Authors: Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN Tags: Curr Gene Ther Source Type: research